MSLN and familial pancreatic carcinoma: In the meantime, mesothelin-targeting ADC (DMOT4039A) demonstrated partial responses in a subset of pancreatic cancer patients in a phase I trial, with a manageable safety profile, thereby validating mesothelin as a promising target in pancreatic cancer [154].